These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10394049)

  • 1. Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients.
    Adams HP; Wagner S; Sobel DF; Slivka LS; Sipe JC; Romine JS; Beutler E; Koziol JA
    Eur Neurol; 1999 Jul; 42(1):52-63. PubMed ID: 10394049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole brain volume changes in patients with progressive MS treated with cladribine.
    Filippi M; Rovaris M; Iannucci G; Mennea S; Sormani MP; Comi G
    Neurology; 2000 Dec; 55(11):1714-8. PubMed ID: 11113227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
    Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L;
    Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
    Elliott C; Belachew S; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Fecker J; Model F; Wei W; Arnold DL
    Brain; 2019 Sep; 142(9):2787-2799. PubMed ID: 31497864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group.
    Rice GP; Filippi M; Comi G
    Neurology; 2000 Mar; 54(5):1145-55. PubMed ID: 10720289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New hypointense lesions on MRI in relapsing-remitting multiple sclerosis patients.
    Wagner S; Adams H; Sobel DF; Slivka LS; Sipe JC; Romine JS; Koziol JA
    Eur Neurol; 2000; 43(4):194-200. PubMed ID: 10828648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS).
    Fazekas F; Sørensen PS; Filippi M; Ropele S; Lin X; Koelmel HW; Fernandez O; Pozzilli C; O'Connor P; Enriquez MM; Hommes OR;
    Mult Scler; 2005 Aug; 11(4):433-40. PubMed ID: 16042226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.
    Zivadinov R; Dwyer M; Barkay H; Steinerman JR; Knappertz V; Khan O
    J Neurol; 2015 Mar; 262(3):648-53. PubMed ID: 25542295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
    Comi G; Cook SD; Giovannoni G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett AC; Viglietta V; Greenberg SJ
    J Neurol; 2013 Apr; 260(4):1136-46. PubMed ID: 23263473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of cladribine on T(1) 'black hole' changes in progressive MS.
    Filippi M; Rovaris M; Rice GP; Sormani MP; Iannucci G; Giacomotti L; Comi G
    J Neurol Sci; 2000 May; 176(1):42-4. PubMed ID: 10865091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis.
    Miller DH; Molyneux PD; Barker GJ; MacManus DG; Moseley IF; Wagner K
    Ann Neurol; 1999 Dec; 46(6):850-9. PubMed ID: 10589537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI measures and their relations with clinical disability in relapsing-remitting and secondary progressive multiple sclerosis.
    Giugni E; Pozzilli C; Bastianello S; Gasperini C; Paolillo A; Koudriavtseva T; Frontoni M; Farina D; Bozzao L
    Mult Scler; 1997 Aug; 3(4):221-5. PubMed ID: 9372503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.
    Truyen L; van Waesberghe JH; van Walderveen MA; van Oosten BW; Polman CH; Hommes OR; Adèr HJ; Barkhof F
    Neurology; 1996 Dec; 47(6):1469-76. PubMed ID: 8960729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of multiple sclerosis and other autoimmune diseases with cladribine.
    Beutler E; Sipe J; Romine J; McMillan R; Zyroff J; Koziol J
    Semin Hematol; 1996 Jan; 33(1 Suppl 1):45-52. PubMed ID: 8714617
    [No Abstract]   [Full Text] [Related]  

  • 15. Defining multiple sclerosis disease activity using MRI T2-weighted difference imaging.
    Lee MA; Smith S; Palace J; Matthews PM
    Brain; 1998 Nov; 121 ( Pt 11)():2095-102. PubMed ID: 9827769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asymmetries in the spatial distributions of enhancing lesions and black holes in relapsing-remitting MS.
    Koziol JA; Wagner S; Sobel DF; Feng AC; Adams HP
    J Clin Neurosci; 2005 Nov; 12(8):895-901. PubMed ID: 16249086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The treatment of chronic progressive multiple sclerosis with cladribine.
    Beutler E; Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1716-20. PubMed ID: 8643695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T1 hypointense lesion load in secondary progressive multiple sclerosis: a comparison of pre versus post contrast loads and of manual versus semi automated threshold techniques for lesion segmentation.
    O'Riordan JI; Gawne Cain M; Coles A; Wang L; Compston DA; Tofts P; Miller DH
    Mult Scler; 1998 Oct; 4(5):408-12. PubMed ID: 9839300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
    Cree BAC; Bowen JD; Hartung HP; Vermersch P; Hughes B; Damian D; Hyvert Y; Dangond F; Galazka A; Grosso M; Jones DL; Leist TP
    Mult Scler Relat Disord; 2021 Apr; 49():102695. PubMed ID: 33578191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of cladribine treatment in multiple sclerosis.
    Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J; Beutler E
    Mult Scler; 1996 Jul; 1(6):343-7. PubMed ID: 9345414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.